 |
市场调查报告书
商品编码
1672769
GLP-1 受体促效剂市场依药物类别、给药途径、应用、通路及地区划分GLP-1 Receptor Agonist Market, By Drug Class, By Route of Administration, By Application, By Distribution Channel, By Geography |
||||||
2025 年全球 GLP-1 受体促效剂市场规模估计为 281.9 亿美元，预计到 2032 年将达到 635.4 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 12.3%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025 年市场规模 | 281.9亿美元 |
| 效能资料 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期：2025 年至 2032 年复合年增长率 | 12.30％ | 2032 年金额预测 | 635.4亿美元 |
GLP-1受体促效剂是治疗第2型糖尿病的重要抗糖尿病药物。它们模仿内源性Glucagon-Like Peptide-1(GLP-1) 的作用，GLP-1 是一种餐后分泌的胜肽激素，可刺激胰岛素分泌并以葡萄糖依赖性方式抑制升糖素分泌。透过结合并活化 GLP-1 受体，这些药物可诱导胰岛素分泌、抑制升糖素分泌、抑制食慾并促进糖尿病患者减肥。与其他治疗类别相比，卓越的血糖控制和低低血糖风险使其成为一种有吸引力的选择，从而推动了市场成长。
市场动态
全球 GLP-1 受体促效剂市场的成长是由世界范围内糖尿病盛行率的上升以及 GLP-1 受体促效剂优异的治疗效果所推动的。肥胖问题的加剧增加了罹患第 2 型糖尿病的风险，对更有效的治疗方法的需求也日益增加。然而，高昂的开发成本和严格的监管核准可能会阻碍市场成长。具有改良配方、灵活剂量选择、更长作用时间及多种药物组合等特点的新产品的推出，可能带来成长机会。开发商正在投入研发力量，开发口服製剂，以扩大临床应用并提高患者的便利性。
研究的主要特点
本报告对全球 GLP-1 受体促效剂市场进行了详细分析，并展示了预测期（2025-2032 年）的市场规模（以十亿美元计）和年复合成长率（CAGR%），以 2024 年为基准年。
它还强调了各个领域的潜在商机并解释了该市场的有吸引力的投资提案矩阵。
它还提供了关于市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的主要考察。
本报告根据公司亮点、产品系列、关键亮点、绩效和策略等参数，介绍了全球 GLP-1 受体促效剂市场的主要企业。
该研究涉及的主要企业包括 Novo Nordisk A/S、Eli Lilly and Company、Sanofi 等。
本报告的见解将使负责人和企业经营团队能够就未来产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。
全球 GLP-1 受体促效剂市场报告针对该行业的各个相关人员，例如投资者、供应商、产品製造商、分销商、新进业者和金融分析师。
相关人员将透过全球 GLP-1 受体促效剂市场分析中使用的各种策略矩阵更轻鬆地做出决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
- 一致的机会图 (COM)
第三章市场动态、法规与趋势分析
- 市场动态
- 驱动程式
- 限制因素
- 机会
- 影响分析
- 市场趋势
- 监管情景
- 收购和合作场景
- 资金筹措和投资
- PEST分析
- 波特的分析
4. 全球 GLP-1 受体促效剂市场 - 冠状病毒 (COVID-19) 大流行的影响
- 整体影响
- 政府倡议
- COVID-19 市场影响
5. 2020 年至 2032 年全球 GLP-1 受体促效剂市场（依药物类别划分）（十亿美元）
- 介绍
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- albiglutide
- Semaglutide
6. 2020 年至 2032 年按给药途径分類的全球 GLP-1 受体促效剂市场（十亿美元）
- 介绍
- 肠外
- 口服
7. 2020 年至 2032 年全球 GLP-1 受体促效剂市场（按应用划分）（十亿美元）
- 介绍
- 2 型糖尿病
- 肥胖
- 肝硬化
- 非酒精性脂肪肝
- 其他的
8. 2020-2032 年全球 GLP-1 受体促效剂市场按分销管道划分（十亿美元）
- 介绍
- 医院药房
- 零售药局
- 网路药局
9. 2020 年至 2032 年全球 GLP-1 受体促效剂市场（按地区划分）（十亿美元）
- 介绍
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
- 非洲
第十章 竞争格局
- 公司简介
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
- Perrigo Company PLC
- 3M Company
- Bausch Health
- Taro Pharmaceutical Industries
- Novan Inc.
- Serum Institute of India Pvt. Ltd.
- Orgenesis bIoTech company
- Verrica Pharmaceuticals
- AbbVie Inc.
- Lee's Pharmaceutical Holdings Ltd
- Cassiopea
- Glenmark Pharmaceuticals
第 11 章 分析师建议
- 兴衰
- 一致的机会地图
第 12 章参考文献与调查方法
- 参考
- 调查方法
Global GLP-1 Receptor Agonist Market is estimated to be valued at USD 28.19 Bn in 2025 and is expected to reach USD 63.54 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.3% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 28.19 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 12.30% | 2032 Value Projection: | USD 63.54 Bn |
GLP-1 receptor agonists are an important class of anti-diabetic drugs for the treatment of type 2 diabetes. These mimic the effects of endogenous glucagon-like peptide-1 (GLP-1), a peptide hormone released after eating which stimulates insulin secretion and suppresses glucagon secretion in a glucose-dependent manner. By binding to and activating the GLP-1 receptor, these drugs induce insulin secretion, inhibit glucagon release, suppress appetite and promote weight loss in diabetic patients. Their superior glucose control efficacy and low risk of hypoglycemia as compared to other classes make them an attractive option, thus, driving the market growth.
Market Dynamics:
Global GLP-1 receptor agonist market growth is driven by growing prevalence of diabetes worldwide coupled with the superior therapeutic efficacy of GLP-1 receptor agonists. Rising levels of obesity can increase the risk of type 2 diabetes, thus, boosting demand for more effective medical treatments. However, high development costs and stringent regulatory approvals can hamper the market growth. New product launches featuring improved formulations, flexible dosing options, longer duration of action and multi-indication usage can offer growth opportunities. Manufacturers are investing in R&D to expand clinical indications and develop oral versions of these drugs to improve patient convenience.
Key Features of the Study:
This report provides in-depth analysis of the global GLP-1 receptor agonist market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global GLP-1 receptor agonist market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company and Sanofi
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global GLP-1 receptor agonist market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global GLP-1 receptor agonist market
Detailed Segmentation-
- By Drug Class
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Albiglutide
- Semaglutide
- By Route of Administration
- Parenteral
- Oral
- By Application
- Type 2 Diabetes Mellitus
- Obesity
- Liver Cirrhosis
- Non-alcoholic Steatohepatitis
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
- Perrigo Company PLC
- 3M Company
- Bausch Health
- Taro Pharmaceutical Industries
- Novan Inc.
- Serum Institute of India Pvt. Ltd.
- Orgenesis biotech company
- Verrica Pharmaceuticals
- AbbVie Inc.
- Lee's Pharmaceutical Holdings Ltd
- Cassiopea
- Glenmark Pharmaceuticals
- Cassiopea
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global GLP-1 Receptor Agonist Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the Market
5. Global GLP-1 Receptor Agonist Market, By Drug Class, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Exenatide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liraglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Dulaglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lixisenatide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Albiglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Semaglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global GLP-1 Receptor Agonist Market, By Route of Administration, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global GLP-1 Receptor Agonist Market, By Application, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Type 2 Diabetes Mellitus
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Obesity
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liver Cirrhosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Non-alcoholic Steatohepatitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global GLP-1 Receptor Agonist Market, By Distribution Channel, 2020 - 2032, (USD Bn)
- Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global GLP-1 Receptor Agonist Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2032
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Eli Lilly and Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
- Perrigo Company PLC
- 3M Company
- Bausch Health
- Taro Pharmaceutical Industries
- Novan Inc.
- Serum Institute of India Pvt. Ltd.
- Orgenesis biotech company
- Verrica Pharmaceuticals
- AbbVie Inc.
- Lee's Pharmaceutical Holdings Ltd
- Cassiopea
- Glenmark Pharmaceuticals
- Eli Lilly and Company
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About Us and Sales Contact
